MarketPeel
Insider Trading Intelligence
FS

Farrell Simon

TRVI
CHIEF COMMERCIAL OFFICER · TREVI THERAPEUTICS, INC. · CIK 0001965585
FILING MIX · LIFETIME61%/39%
BUYS
11
SELLS
7
TOTAL VALUE
$883.3K
COMPANIES
1
ACTIVE SINCE
Feb 2023
HOLDINGS NOW
160,000
AVG SELL PX
$6.75
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Farrell Simon, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%+7.74%+1.17%+6.57%+6.57%
14d2+0.00%+5.44%+2.72%+2.72%+2.72%
30d2+100.00%-11.04%-1.84%-9.20%-9.20%
60d2+0.00%+8.73%+0.97%+7.76%+7.76%
90d2+0.00%+5.60%+7.30%-1.70%-1.70%
180d2+0.00%+15.49%+15.81%-0.32%-0.32%
1y2+0.00%+93.74%+21.16%+72.58%+72.58%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TRVI · 160,000 shares · as of Feb 19, 2026
056,375112,750169,125225,500202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 11 buys / 7 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
160,000160,000Feb 19, 2026Feb 20, 2026View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,000110,400May 31, 2025Jun 3, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
63,813$3.91$249.5K126,963Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Commercial Officer
17,5000Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,350$7.15$31.1K76,900Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
31,250$0.51$16.0K158,213Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,40038,400Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
17,500$3.21$56.2K63,150Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
76,963$6.73$517.8K81,250Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Commercial Officer
31,25018,750Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Commercial Officer
63,81311,187Mar 10, 2025Mar 12, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
225,500225,500Feb 18, 2025Feb 20, 2025View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
175,000175,000Feb 15, 2024Feb 16, 2024View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
6,250$0.51$3.2K45,650Jun 20, 2023Jun 21, 2023View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Commercial Officer
6,25050,000Jun 20, 2023Jun 21, 2023View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASE
Chief Commercial Officer
18,750$0.51$9.6K39,400Mar 7, 2023Mar 7, 2023View →
TRVI
TREVI THERAPEUTICS, INC.
SALE
Chief Commercial Officer
18,75056,250Mar 7, 2023Mar 7, 2023View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Feb 16, 2023Feb 16, 2023View →
Other insiders · TRVI
Loading peer insiders…
About this filer
CIK 0001965585
ROLE
Chief Commercial Officer
PRIMARY
TRVI
COMPANIES
1
ACTIVE SINCE
Feb 2023
MARKETPEEL · /INSIDER/0001965585DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback